255 related articles for article (PubMed ID: 12634368)
1. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
Wolbank S; Kunert R; Stiegler G; Katinger H
J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
[TBL] [Abstract][Full Text] [Related]
2. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
[TBL] [Abstract][Full Text] [Related]
3. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
[TBL] [Abstract][Full Text] [Related]
4. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
5. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
6. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
Li A; Baba TW; Sodroski J; Zolla-Pazner S; Gorny MK; Robinson J; Posner MR; Katinger H; Barbas CF; Burton DR; Chou TC; Ruprecht RM
AIDS Res Hum Retroviruses; 1997 May; 13(8):647-56. PubMed ID: 9168233
[TBL] [Abstract][Full Text] [Related]
7. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
[TBL] [Abstract][Full Text] [Related]
8. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.
Klein K; Veazey RS; Warrier R; Hraber P; Doyle-Meyers LA; Buffa V; Liao HX; Haynes BF; Shaw GM; Shattock RJ
J Virol; 2013 Nov; 87(21):11604-16. PubMed ID: 23966410
[TBL] [Abstract][Full Text] [Related]
10. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5.
Kunert R; Rüker F; Katinger H
AIDS Res Hum Retroviruses; 1998 Sep; 14(13):1115-28. PubMed ID: 9737583
[TBL] [Abstract][Full Text] [Related]
13. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
[TBL] [Abstract][Full Text] [Related]
14. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
[TBL] [Abstract][Full Text] [Related]
15. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
[TBL] [Abstract][Full Text] [Related]
17. Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells.
Kunert R; Steinfellner W; Purtscher M; Assadian A; Katinger H
Biotechnol Bioeng; 2000 Jan; 67(1):97-103. PubMed ID: 10581440
[TBL] [Abstract][Full Text] [Related]
18. The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.
Peachman KK; Wieczorek L; Matyas GR; Polonis VR; Alving CR; Rao M
Viral Immunol; 2010 Dec; 23(6):627-32. PubMed ID: 21142448
[TBL] [Abstract][Full Text] [Related]
19. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
20. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
